梯瓦制药 TEVA 深沪

已收盘 01-30 16:00:00 美东时间

34.08

+1.010

+3.05%

华盛通

立即下载

最高34.11
今开32.49
成交量 1696.92万股
最低 32.35
昨收 33.07
总市值 390.90亿
52周最高 34.11
市盈率 ^静 27.94
换手率 1.48%
52周最低 12.465
委比 66.32%
总股本 11.47亿
历史最高 69.8535
量比 1.32
振幅 5.32%
历史最低 6.07
每手 1
风险率 5.47%

个股概要

财务分析

公司资料

分红派息

分时图
日k
周k
月k

相关新闻

美股大行评级 | Meta 、IBM、拉姆研究、布林克国际等获多家机构上调目标价；微软、特斯拉、ServiceNow、自动数据处理等遭多家下调评级

今日重点评级关注：Piper Sandler：上调Korro Bio评级至"超配"，目标价从11美元升至30美元；Piper Sandler：维持Nurix Therapeutics"超配"评级，目标价从32美元升至35美元

01-30 17:38
11 Analysts Assess Teva Pharmaceutical Indus: What You Need To Know

Analysts' ratings for Teva Pharmaceutical Indus (NYSE:TEVA) over the last quart...

01-30 03:00
Teva Earnings Call: Innovation Offsets Generics and One-Offs

Teva Pharmaceutical Industries Limited (($TEVA)) has held its Q4 earnings call....

01-29 08:28
Teva's Flagship Drugs Hit $1 Billion Milestone, Raises Confidence In 2026 Outlook

Teva beat fourth-quarter estimates as drug sales surged, led by Austedo and Ajovy, while the company forecast steady earnings and revenue growth for 2026.

01-29 01:22
Teva Pharmaceutical Industries shares are trading lower. The company reported Q4 financial results.

Teva Pharmaceutical Industries shares are trading lower. The company reported Q...

01-28 21:58
Teva projects revenue drop in 2026 despite Q4 beat

Teva Pharmaceutical (TEVA) traded lower in the premarket on Wednesday after the generic drugmaker projected lower-than-expected financials for 2026 and a contraction in its business even as its Q4 202...

01-28 20:36
Teva Pharmaceutical Indus Sees FY2026 Adj EPS $2.57-$2.77 vs $2.73 Est; Sees Sales $16.400B-$16.800B vs $16.889B Est

Teva Pharmaceutical Indus (NYSE:TEVA) is looking for FY2026 Adj EPS of $2.57-$2.77 vs $2.73 analyst estimate. sees sales of $16.400 billion-$16.800 billion vs $16.889 billion analyst estimate.

01-28 20:03
Teva Pharmaceutical Indus Q4 Adj. EPS $0.96 Beats $0.68 Estimate, Sales $4.711B Beat $4.368B Estimate

Teva Pharmaceutical Indus (NYSE:TEVA) reported quarterly earnings of $0.96 per share which beat the analyst consensus estimate of $0.68 by 41.38 percent. This is a 35.21 percent increase over earnings of $0.71 per share

01-28 20:01
FOCUS-Drugmakers turn to AI to speed trials, regulatory submissions

FOCUS-Drugmakers turn to AI to speed trials, regulatory submissions Pharmaceutical companies describe AI benefits for tedious work Novartis says AI cut trial site selection from weeks to a two-hour meeting Drugmakers use AI to draft regulator-ready filings By Maggie Fick and Michael Erman SAN FRANCI

01-26 19:00
Novo sued for working with Teva to delay generic Victoza

A class action lawsuit was filed in New York federal court on Friday accusing Novo Nordisk (NVO) of running a "pay-for-delay" scheme with Teva Pharmaceutical (TEVA) to unlawfully delay the market entr...

01-24 22:10

派息除权日	每股总股息	派息日期
2017-11-27	0.07	2017-12-12
2017-08-25	0.07	2017-09-14
2017-06-01	0.29	2017-06-22
2017-02-28	0.29	2017-03-20
2016-12-01	0.29	2016-12-20
2016-08-18	0.29	2016-09-08
2016-05-20	0.29	2016-06-07
2016-02-25	0.29	2016-03-14
2015-11-13	0.29	2015-12-03
2015-08-18	0.29	2015-09-03
2015-05-15	0.29	2015-06-04
2015-02-17	0.29	2015-03-03
2014-11-13	0.27	2014-12-02
2014-08-19	0.29	2014-09-04
2014-05-16	0.30	2014-06-02
2014-02-20	0.29	2014-03-10
2013-11-18	0.28	2013-12-03
2013-08-16	0.27	2013-09-03
2013-05-16	0.27	2013-06-03
2013-02-19	0.27	2013-03-07
2012-11-13	0.20	2012-12-03
2012-08-13	0.21	2012-09-04
2012-05-17	0.20	2012-06-04
2012-02-23	0.20	2012-03-15
2011-11-09	0.17	2011-12-07
2011-08-04	0.20	2011-08-25
2011-05-19	0.20	2011-06-07
2011-02-10	0.22	2011-03-07
2010-11-08	0.17	2010-12-06
2010-08-02	0.17	2010-08-26
2010-05-10	0.16	2010-06-04
2010-02-19	0.16	2010-03-17
2009-11-06	0.13	2009-12-04
2009-08-03	0.12	2009-08-27
2009-05-08	0.12	2009-06-03
2009-02-23	0.11	2009-03-19
2008-11-07	0.09	2008-12-05
2008-08-01	0.10	2008-08-27
2008-05-13	0.11	2008-06-05
2008-02-15	0.10	2008-03-13
2007-11-02	0.08	2007-11-28
2007-08-10	0.08	2007-09-06
2007-05-10	0.08	2007-06-05
2007-02-16	0.08	2007-03-15
2006-11-10	0.07	2006-12-06
2006-08-11	0.06	2006-09-08
2006-05-12	0.06	2006-06-07
2006-03-06	0.06	2006-03-30
2005-11-10	0.05	2005-12-07
2005-08-11	0.05	2005-09-07
2005-05-05	0.06	2005-06-01
2005-02-17	0.06	2005-03-17
2004-11-09	0.04	2004-12-06
2004-08-09	0.04	2004-09-07
2004-05-10	0.15	2004-06-07
2004-02-20	0.08	2004-03-22
2003-11-13	0.06	2003-12-12
2003-08-08	0.06	2003-09-08
2003-05-08	0.06	2003-06-06
2003-02-24	0.05	2003-03-24
2002-11-07	0.07	2002-12-06
2002-08-19	0.07	2002-09-16
2002-05-20	0.07	2002-06-17
2002-02-15	0.08	2002-03-18
2001-11-16	0.05	2001-12-17
2001-08-20	0.05	2001-09-17
2001-05-17	0.05	2001-06-15
2001-03-08	0.05	2001-04-06
2000-11-16	0.04	2000-12-15
2000-08-24	0.04	2000-09-21
2000-05-19	0.04	2000-06-19
2000-02-17	0.08	2000-03-27
1999-11-04	0.05	1999-11-30
1999-08-18	0.05	1999-09-13
1999-05-21	0.05	1999-06-15
1999-03-08	0.05	1999-03-30
1998-11-20	0.05	1998-12-11
1998-08-21	0.06	1998-09-11
1998-05-21	0.06	1998-06-22
1998-03-12	0.06	1998-03-31
1997-11-20	0.07	1997-12-09
1997-08-25	0.07	1997-09-11
1997-05-23	0.07	1997-06-12
1997-03-07	0.07	1997-03-26
1996-11-20	0.05	1996-12-09
1996-08-26	0.05	1996-09-12
1996-05-23	0.05	1996-06-12
1996-03-07	0.05	1996-03-26
1995-11-20	0.05	1995-12-07
1995-08-14	0.05	1995-08-30
1995-05-17	0.05	1995-06-07
1995-03-07	0.05	1995-04-04
1994-11-15	0.05	1994-12-13
1994-08-09	0.05	1994-09-12
1994-05-18	0.05	1994-06-21
1994-03-08	0.05	1994-04-05
1993-11-17	0.04	1994-01-03
1993-08-17	0.04	1993-09-14
1993-05-18	0.03	1993-06-21
1993-04-07	0.06	1993-05-05
1992-11-17	0.04	1992-12-21
1992-08-18	0.04	1992-09-21
1991-11-20	0.04	1991-12-19
1991-08-21	0.04	1991-09-19
1991-05-20	0.04	1991-07-20
1991-03-05	0.04	1991-03-28
1990-11-20	0.04	1990-12-20
1990-08-17	0.04	1990-09-17
1989-05-22	0.04	1989-06-19
1988-12-06	0.04	1988-12-30
1988-09-08	0.04	1988-10-05
1988-06-10	0.03	1988-07-20
1988-04-11	0.03	1988-05-16
1988-02-08	0.03	1988-03-10
1987-10-23	0.03	1987-11-19
1987-07-09	0.04	1987-08-05
1987-06-22	0.03	1987-07-14
1987-02-23	0.03	1987-03-26
1985-09-23	0.02	1985-10-21
1985-06-17	0.02	1985-07-15
1984-01-27	0.02	1984-02-29
1982-08-16	0.40	1982-09-13
1982-08-10	0.06	1982-09-13

公司名称	梯瓦制药
行业分类	制药
业务描述	Teva Pharmaceutical Industries Ltd. engages in the development, production, and sale of medicines. It operates through the following geographical segments: United States, Europe, and International Markets. The United States segment focuses on therapeutic area of central nervous system (CNS) portfolio, and is involved in the distribution business of generic, biosimilar and medicines, and over-the-counter (OTC) pharmaceutical products from the firm and third-party manufacturers to independent retail pharmacies, pharmacy retail chains, hospitals, and physician offices in the United States. The Europe segment offers OTC portfolio including SUDOCREM, NasenDuo, DICLOX FORTE, OLFEN Max, and FLEGAMINA brands in European Union, the United Kingdom, and certain other European countries. The International Markets segment provides its products to countries such as Canada, Israel, Russia, Latin America, and Japan. The company was founded in 1901 and is headquartered in Tel Aviv, Israel.

梯瓦制药 TEVA 深 沪

34.08

个股概要

财务分析

公司资料

相关新闻

分红派息

相关新闻

公司简介

梯瓦制药 TEVA 深沪